Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (437)	4/5/2003 12:47:17 AM
From: scaram(o)uche	Respond to of 469

hmmmmm....... I forgot about that. There's tons of this sort of stuff around...... niaid.nih.gov nature.com bioch.ox.ac.uk BVDV is an enveloped, positive sense, single strand RNA virus, as is the (first blush) causative agent of SARS. If you'd have thought about this earlier in the day and hit IRC with the info, you probably could have driven OGSI to about $500. ;-) Thanks!

To: tuck who wrote (437)	4/5/2003 1:30:46 PM
From: scaram(o)uche	Respond to of 469

>> But..... apart from the obvious indications, I believe that NB-GJ could have use for a variety of ACUTE indications. << Message 18339083 I still believe this. I think it's CRAZY that more pharmas aren't in the mix with Celltech, Merlin Bioscience, etc. They just never learn. They want to look good for their shareholders and save money when everything is cheap. The reason that Novartis is becoming dominant? During the days of Sandoz and Ciba, the focus was on a bright future rather than next quarter's bottom line.